Thyroid Translocation and Mutation Panel
Ordering Recommendation

Use in individuals diagnosed with or suspected of having papillary or follicular thyroid carcinoma in conjunction with cytologic or histologic and clinical information. Detects mutations (BRAF, KRAS, NRAS, and HRAS genes) and translocations (RET-CCDC6(PTC1), RET-NCOA4(PTC3), and PAX8-PPARG).

Polymerase Chain Reaction/Pyrosequencing
DNA isolation: Sun-Sat
Assay: Mon, Thu
12-14 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Tumor tissue. 
Specimen Preparation
Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport tissue block or 5 unstained 5-micron slides. (Min: 3 slides) Tissue block will be returned after testing.
A Fine Needle Aspirate (FNA) smear may also be submitted. Prepare FNA smear with Diff-Quik or equivalent stain by standard methods (air-dried slides are preferred). Number of slides needed is dependent on the tumor cellularity of the smear. (Min: 2 slides) Slides will be destroyed during testing process and will not be returned to client.
Transport of a block and/or slide(s) in a tissue transport kit is preferred (ARUP supply #47808) available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787.
FNA specimens stored in saline, PreservCyt or CytoLyt are also acceptable. 
Storage/Transport Temperature
Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months. 
Unacceptable Conditions
Less than 25 percent tumor. Specimens fixed/processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives. Decalcified specimens. FNA smears with less than 50 tumor cells. 
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
FNA in Saline: Ambient: 48 hours; Refrigerated: 48 hours ;  Frozen: Acceptable 
Reference Interval
Interpretive Data
Refer to report.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

This panel will detect and report mutations in BRAF codon 600, KRAS codons 12/13/61, NRAS codons 12/13/61, HRAS codons 12/13/61 and translocations PAX8-PPARG, RET-CCDC6 and RET-NCOA4.
CPT Code(s)
81210; 81275; 81276; 81311; 81403; 81401; 81479; add 88381 for FFPE
Component Test Code*Component Chart NameLOINC
2002148Block ID57723-9
2012756BRAF Mutation Detection, Thyroid58483-9
2012757KRAS Mutation Detection, Thyroid21702-6
2012758NRAS Mutation Detection, Thyroid21719-0
2012759HRAS Mutation Detection, Thyroid21698-6
2012761RET-PTC Translocation Detection, Thyroid
2012763PAX8-PPARG Translocation, Thyroid
2012765Thyroid Panel Result Summary35474-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.